Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DOTAP:Chol-TUSC2 + erlotinib
- Development stage
- Unknown
- Lead developer
- Genprex
- Modality
- Small Molecules, Gene Therapies
- Administration
- Intravenous, Oral
01
Overview
DOTAP:Chol-TUSC2 + erlotinib is a combination therapy consisting of DOTAP:Chol-TUSC2 (a gene therapy) and erlotinib hydrochloride (an EGFR inhibitor). DOTAP:Chol-TUSC2 is a nanoparticle delivery system that contains the tumor suppressor gene TUSC2 (also known as FUS1) complexed with DOTAP:Cholesterol liposomes. This gene therapy aims to restore TUSC2 expression in cancer cells, as TUSC2 is frequently deleted or silenced in lung cancer. Erlotinib is an EGFR tyrosine kinase inhibitor that blocks a protein on tumor cells that may control tumor growth and survival. The combination therapy shows enhanced antitumor efficacy compared to either treatment alone, particularly in wild-type EGFR non-small cell lung cancer (NSCLC) cells that are typically resistant to erlotinib. The mechanism involves inactivation of multiple pathways including FGFR2 and mTOR signaling.
- Other names
- REQORSA + erlotinibQuaratusugene Ozeplasmid + erlotinib
02
Targets
TUSC2 (Tumor suppressor candidate 2)mTOR (Mammalian target of rapamycin kinase)EGFR T790M (Epidermal growth factor receptor T790M mutant)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on DOTAP:Chol-TUSC2 + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DOTAP:Chol-TUSC2 + erlotinib.